Dirk Sibbing/LinkedIn
Nov 17, 2025, 05:31
Dirk Sibbing: New Data Strengthen the Case for Prasugrel in ACS
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Following ISAR-REACT 5 and the recently published large Danisch registry in > 10,000 pts more data is accumulating that benefits praugrel over ticagrelor for PCI in ACS patients.
See the interesting coverage and analysis with comments from Sripal Bangalore and Ajay Kirtane on TCTMD on TUXEDO-2, a randomized comparison that focused on diabetic patients with multivessel disease undergoing PCI.”
Find more information here.
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration
-
May 24, 2026, 15:33Mohammed Zubair: AI-Driven Innovation in Stroke Diagnosis and Medical Imaging
-
May 24, 2026, 14:26Salome Mekhuzla: World Health Assembly Adopts Historic Global Resolution for Hemophilia and Bleeding Disorders
-
May 24, 2026, 13:10Thomas Pincez: Emerging Challenges in Sickle Cell Disease Gene Therapy and Cancer Risk
-
May 24, 2026, 12:04Kalpana Gupta Shekhawat: Ferritin Is More Than an Iron Marker
-
May 24, 2026, 11:50Peter Zdziarski: Making Rare Disease Research More Human
-
May 24, 2026, 11:39Bram Berkelmans: Donating with a View
-
May 24, 2026, 11:28Ratiporn Chinthammit: A Meaningful Exchange in aHUS and PNH Education